Lucid Diagnostics Announces Closing of Public Offering of Common Stock [Yahoo! Finance]
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: Yahoo! Finance
the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.00 per share. Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics) The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $26.9 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. Canaccord Genu
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]Yahoo! Finance
- PAVmed Provides Business Update and Reports Third Quarter 2025 Financial ResultsPR Newswire
- PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]Yahoo! Finance
PAVM
Earnings
- 11/13/25 - Beat
PAVM
Analyst Actions
- 10/6/25 - Ascendiant Capital
PAVM
Sec Filings
- 11/13/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 10/31/25 - Form DEF
- PAVM's page on the SEC website